Patents Assigned to Oryzon Genomics, S.A.
  • COMBINATIONS OF LSD1 INHIBITORS AND MENIN INHIBITORS FOR TREATING CANCER
    Publication number: 20260151399
    Abstract: The instant invention relates to combinations of an LSD1 inhibitor (or a pharmaceutically acceptable salt thereof) and a Menin inhibitor (or a pharmaceutically acceptable salt thereof). The combinations are particularly useful for treating cancer, including hematological cancers, such as acute myeloid leukemia or myelodysplastic syndrome.
    Type: Application
    Filed: November 24, 2023
    Publication date: June 4, 2026
    Applicant: ORYZON GENOMICS, S.A.
    Inventors: Natalia SACILOTTO, Robert SOLIVA SOLIVA
  • Combinations of LSD1 inhibitors for use in the treatment of solid tumors
    Patent number: 12564559
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: March 3, 2026
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Mark D. Demario, Tamara Maes, William E. Pierceall, Fiona Mack, Serena Lunardi
  • METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS
    Publication number: 20250295660
    Abstract: The present invention relates to an LSD1 inhibitor for use in the treatment of an NF1-mutant tumor, i.e. a tumor having one or more mutations or genetic alterations affecting the NF1 gene. The invention likewise provides methods of treating an NF1-mutant tumor in a subject in need thereof, comprising administering a therapeutically effective amount of an LSD1 inhibitor to the subject.
    Type: Application
    Filed: May 9, 2023
    Publication date: September 25, 2025
    Applicant: ORYZON GENOMICS, S.A.
    Inventors: Robert SOLIVA SOLIVA, Natalia SACILOTTO, Cristina MASCARÓ CRUSAT, David ROTLLANT POZO
  • METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS
    Publication number: 20250275969
    Abstract: The present invention relates to an LSD1 inhibitor for use in the treatment of malignant peripheral nerve sheath tumor (MPNST). The invention likewise provides methods of treating MPNST in a subject in need thereof, comprising administering a therapeutically effective amount of an LSD1 inhibitor to the subject.
    Type: Application
    Filed: May 9, 2023
    Publication date: September 4, 2025
    Applicant: ORYZON GENOMICS, S.A.
    Inventors: Natalia SACILOTTO, Robert SOLIVA SOLIVA, Cristina MASCARÓ CRUSAT, David ROTLLANT POZO, Concepción LÁZARO GARCÍA,
  • STABLE PHARMACEUTICAL FORMULATION
    Publication number: 20210228490
    Abstract: The present invention relates to a pharmaceutical composition of (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, a process for the preparation thereof and its use in the treatment of diseases.
    Type: Application
    Filed: May 6, 2019
    Publication date: July 29, 2021
    Applicant: Oryzon Genomics, S.A.
    Inventors: Reto MAURER, Patrick BUSSON, Georg HUMMEL
  • Method of treating multiple sclerosis employing a LSD1-inhibitor
    Patent number: 10780081
    Abstract: Provided herein are methods for treating multiple sclerosis using (?) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 22, 2020
    Assignee: Oryzon Genomics, S.A.
    Inventors: Tamara Maes, Cristina Mascarò Crusat, David Rotllant Pozo
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 10329256
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Combinations of LSD1 inhibitors for use in the treatment of solid tumors
    Patent number: 10265279
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: April 23, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Mark D. Demario, Tamara Maes, William E. Pierceall, Fiona Mack, Serena Lunardi
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 10233178
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte Martinez
  • Solid forms
    Patent number: 10221125
    Abstract: The instant invention relates to novel solid forms of the compound of formula (I) or salts thereof as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: March 5, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Ralph Diodone, Urs Schwitter, René Trussardi
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 9944601
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: April 17, 2018
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Lysine demethylase inhibitors for myeloproliferative disorders
    Patent number: 9908859
    Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: March 6, 2018
    Assignee: Oryzon Genomics, S.A.
    Inventors: Jonathan Alleman Baker, Julio Castro Palomino, Matthew Colin Thor Fyfe, Tamara Maes, Marc Martinell Pedemonte
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 9708309
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 18, 2017
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte-Martinez
  • Cyclopropylamine derivatives useful as LSD1 inhibitors
    Patent number: 9676701
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: June 13, 2017
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Matthew Colin Thor Fyfe, Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Marc Martinell Pedemonte, Maria de los Angeles Estiarte-Martinez, Nuria Valls Vidal
  • Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
    Patent number: 9616058
    Abstract: The present invention relates to the use of potent selective LSD inhibitors and LSD/MAO-B inhibitors for treating or preventing viral infections. Furthermore, the present invention relates to the new use of cyclopropylamine acetamide derivatives or cyclopropylamine derivatives, as defined herein, for treating or preventing viral infection and treating or preventing reactivation of a virus after latency.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: April 11, 2017
    Assignee: Oryzon Genomics, S.A.
    Inventors: Julio Cesar Castro Palomino Laria, Alberto Ortega Muñoz, Nathalie Guibourt, Jonathan Alleman Baker
  • Cyclopropylamine derivatives useful as LSD1 inhibitors
    Patent number: 9006449
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: April 14, 2015
    Assignee: Oryzon Genomics, S.A.
    Inventors: Matthew Colin Thor Fyfe, Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Marc Martinell Pedemonte, Maria de los Ángeles Estiarte-Martinez, Nuria Valls Vidal
  • Phenylcyclopropylamine derivatives and their medical use
    Patent number: 8993808
    Abstract: The present invention relates to phenylcyclopropylamine derivatives. In particular, pharmaceutical compositions comprising phenylcyclopropylamine derivatives are provided. The compounds of this invention can, inter alia, be used for the treatment and the prevention of cancer as well as neurodegenerative diseases or disorders.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: March 31, 2015
    Assignee: Oryzon Genomics, S.A.
    Inventors: Nathalie Guibourt, Alberto Ortega Munoz, Julio Castro-Palomino Laria
  • Oxidase inhibitors and their use
    Patent number: 8524717
    Abstract: The invention relates to phenylcyclopropylamine acetamide derivatives and their use in treating diseases.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: September 3, 2013
    Assignee: Oryzon Genomics, S.A.
    Inventors: Nathalie Guibourt, Alberto Ortega Munoz, Julio Castro-Palomino Laria
  • Oxidase inhibitors and their use
    Publication number: 20110263604
    Abstract: The invention relates to phenylcyclopropylamine acetamide derivatives and their use in treating diseases.
    Type: Application
    Filed: April 18, 2011
    Publication date: October 27, 2011
    Applicant: Oryzon Genomics, S.A.
    Inventors: Nathalie Guibourt, Alberto Ortega Munoz, Julio Castro-Palomino Laria
  • Molecular diagnostic method and treatment in dementia with Lewy bodies
    Publication number: 20100285483
    Abstract: The invention describes methods of molecular diagnosis of a concrete form of ?-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.
    Type: Application
    Filed: May 11, 2010
    Publication date: November 11, 2010
    Applicant: Oryzon Genomics, S.A.
    Inventors: Tamara Maes, Carlos Buesa Arjol, Marta Barrachina Castillo, Isidro Ferrer Abizanda